7[2]World Health Organization,International Society of Hypertension Writing Group.2003 World Health Organization (WHO)/International Socitey of Hypertension (ISH) statement on management of hypertension (Guidelines and recommendations)[J].Journal of Hypertension,2003,21 (11):1983.
8[5]Liu Ls,Wang Jg,Gong Ls,et al.Comparison of active treatment and placebo in old chinese with isolated systolic hypertension[J].J Hypertens,199 8,16(12 Pt 1):1823.
9[6]Hansson L,Lindholm LH,Niskanen L,et al.Effect of angiotension-eonverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captropril Prevention Project (CAPPP)randomized trial[J].Lancet,1999,353:611.
10[7]Brown MJ,Palmer CR,Castaigne A,et al.Morbidity and mortality in patients randomised to double-blind treatment with a long acting calcium-channel blocker or diuretic in the international Nifedipine GITS study:Intervention as a goal in hypertension.Treatment(INSIGHT)[J].Lancet,2000,356:366.
